Table of Contents
1. Research Framework
1.1. Research Objective
1.2. Product Overview
1.3. Market Segmentation
2. Executive Summary
3. Global Drug Discovery Services Market Insights
3.1. Industry Value Chain Analysis
3.2. DROC Analysis
3.2.1. Growth Drivers
3.2.1.1. Growing prevalence of chronic diseases
3.2.1.2. Outsourcing of drug discovery activities
3.2.1.3. Increasing R&D expenditure
3.2.2. Restraints
3.2.2.1. Stringent regulatory requirements
3.2.2.2. High failure rates
3.2.3. Opportunities
3.2.3.1. Emergence of personalized medicine
3.2.3.2. Increasing focus on rare diseases and orphan drugs
3.2.4. Challenges
3.2.4.1. Ethical concerns and public perception
3.3. Technology Advancements/Recent Developments
3.4. Regulatory Framework
3.5. Porter's Five Forces Analysis
3.5.1. Bargaining Power of Suppliers
3.5.2. Bargaining Power of Buyers
3.5.3. Threat of New Entrants
3.5.4. Threat of Substitutes
3.5.5. Intensity of Rivalry
3.6. Global Drug Discovery Services Market Overview
3.7. Market Size & Forecast, 2019-2029
3.7.1. By Value (USD Billion)
3.8. Market Share & Forecast
3.8.1. By Type
3.8.1.1. Chemistry Services
3.8.1.2. Biology Services
3.8.2. By Process
3.8.2.1. Target Validation
3.8.2.2. Target Selection
3.8.2.3. Hit-To-Lead Identification
3.8.2.4. Candidate Validation
3.8.2.5. Lead Optimization
3.8.3. By Drug Type
3.8.3.1. Biologics
3.8.3.2. Small Molecule Drugs
3.8.4. By Therapeutic Area
3.8.4.1. Neurology
3.8.4.2. Infectious & Immune System Diseases
3.8.4.3. Digestive System Diseases
3.8.4.4. Oncology
3.8.4.5. Others
3.8.5. By End User
3.8.5.1. Pharmaceutical & Biotechnology Companies
3.8.5.2. Academic Institutes
3.8.5.3. Others
3.8.6. By Region
3.8.6.1. North America
3.8.6.2. Europe
3.8.6.3. Asia Pacific (APAC)
3.8.6.4. Latin America (LATAM)
3.8.6.5. Middle East and Africa (MEA)
4. North America Drug Discovery Services Market
4.1.1. Market Size & Forecast, 2019-2029
4.1.2. By Value (USD Billion)
4.2. Market Share & Forecast
4.2.1. By Type
4.2.2. By Process
4.2.3. By Drug Type
4.2.4. By Therapeutic Area
4.2.5. By End User
4.2.6. By Country
4.2.6.1. United States
4.2.6.1.1. By Type
4.2.6.1.2. By Process
4.2.6.1.3. By Drug Type
4.2.6.1.4. By Therapeutic Area
4.2.6.1.5. By End User
4.2.6.2. Canada
4.2.6.2.1. By Type
4.2.6.2.2. By Process
4.2.6.2.3. By Drug Type
4.2.6.2.4. By Therapeutic Area
4.2.6.2.5. By End User
5. Europe Drug Discovery Services Market
5.1. Market Size & Forecast, 2019-2029
5.1.1. By Value (USD Billion)
5.2. Market Share & Forecast
5.2.1. By Type
5.2.2. By Process
5.2.3. By Drug Type
5.2.4. By Therapeutic Area
5.2.5. By End User
5.2.6. By Country
5.2.6.1. Germany
5.2.6.1.1. By Type
5.2.6.1.2. By Process
5.2.6.1.3. By Drug Type
5.2.6.1.4. By Therapeutic Area
5.2.6.1.5. By End User
5.2.6.2. United Kingdom
5.2.6.2.1. By Type
5.2.6.2.2. By Process
5.2.6.2.3. By Drug Type
5.2.6.2.4. By Therapeutic Area
5.2.6.2.5. By End User
5.2.6.3. Italy
5.2.6.3.1. By Type
5.2.6.3.2. By Process
5.2.6.3.3. By Drug Type
5.2.6.3.4. By Therapeutic Area
5.2.6.3.5. By End User
5.2.6.4. France
5.2.6.4.1. By Type
5.2.6.4.2. By Process
5.2.6.4.3. By Drug Type
5.2.6.4.4. By Therapeutic Area
5.2.6.4.5. By End User
5.2.6.5. Spain
5.2.6.5.1. By Type
5.2.6.5.2. By Process
5.2.6.5.3. By Drug Type
5.2.6.5.4. By Therapeutic Area
5.2.6.5.5. By End User
5.2.6.6. Belgium
5.2.6.6.1. By Type
5.2.6.6.2. By Process
5.2.6.6.3. By Drug Type
5.2.6.6.4. By Therapeutic Area
5.2.6.6.5. By End User
5.2.6.7. Russia
5.2.6.7.1. By Type
5.2.6.7.2. By Process
5.2.6.7.3. By Drug Type
5.2.6.7.4. By Therapeutic Area
5.2.6.7.5. By End User
5.2.6.8. The Netherlands
5.2.6.8.1. By Type
5.2.6.8.2. By Process
5.2.6.8.3. By Drug Type
5.2.6.8.4. By Therapeutic Area
5.2.6.8.5. By End User
5.2.6.9. Rest of Europe
5.2.6.9.1. By Type
5.2.6.9.2. By Process
5.2.6.9.3. By Drug Type
5.2.6.9.4. By Therapeutic Area
5.2.6.9.5. By End User
6. Asia-Pacific Drug Discovery Services Market
6.1. Market Size & Forecast, 2019-2029
6.1.1. By Value (USD Billion)
6.2. Market Share & Forecast
6.2.1. By Type
6.2.2. By Process
6.2.3. By Drug Type
6.2.4. By Therapeutic Area
6.2.5. By End User
6.2.6. By Country
6.2.6.1. China
6.2.6.1.1. By Type
6.2.6.1.2. By Process
6.2.6.1.3. By Drug Type
6.2.6.1.4. By Therapeutic Area
6.2.6.1.5. By End User
6.2.6.2. India
6.2.6.2.1. By Type
6.2.6.2.2. By Process
6.2.6.2.3. By Drug Type
6.2.6.2.4. By Therapeutic Area
6.2.6.2.5. By End User
6.2.6.3. Japan
6.2.6.3.1. By Type
6.2.6.3.2. By Process
6.2.6.3.3. By Drug Type
6.2.6.3.4. By Therapeutic Area
6.2.6.3.5. By End User
6.2.6.4. South Korea
6.2.6.4.1. By Type
6.2.6.4.2. By Process
6.2.6.4.3. By Drug Type
6.2.6.4.4. By Therapeutic Area
6.2.6.4.5. By End User
6.2.6.5. Australia & New Zealand
6.2.6.5.1. By Type
6.2.6.5.2. By Process
6.2.6.5.3. By Drug Type
6.2.6.5.4. By Therapeutic Area
6.2.6.5.5. By End User
6.2.6.6. Indonesia
6.2.6.6.1. By Type
6.2.6.6.2. By Process
6.2.6.6.3. By Drug Type
6.2.6.6.4. By Therapeutic Area
6.2.6.6.5. By End User
6.2.6.7. Malaysia
6.2.6.7.1. By Type
6.2.6.7.2. By Process
6.2.6.7.3. By Drug Type
6.2.6.7.4. By Therapeutic Area
6.2.6.7.5. By End User
6.2.6.8. Singapore
6.2.6.8.1. By Type
6.2.6.8.2. By Process
6.2.6.8.3. By Drug Type
6.2.6.8.4. By Therapeutic Area
6.2.6.8.5. By End User
6.2.6.9. Vietnam
6.2.6.9.1. By Type
6.2.6.9.2. By Process
6.2.6.9.3. By Drug Type
6.2.6.9.4. By Therapeutic Area
6.2.6.9.5. By End User
6.2.6.10. Rest of APAC
6.2.6.10.1. By Type
6.2.6.10.2. By Process
6.2.6.10.3. By Drug Type
6.2.6.10.4. By Therapeutic Area
6.2.6.10.5. By End User
7. Latin America Drug Discovery Services Market
7.1. Market Size & Forecast, 2019-2029
7.1.1. By Value (USD Billion)
7.2. Market Share & Forecast
7.2.1. By Type
7.2.2. By Process
7.2.3. By Drug Type
7.2.4. By Therapeutic Area
7.2.5. By End User
7.2.6. By Country
7.2.6.1. Brazil
7.2.6.1.1. By Type
7.2.6.1.2. By Process
7.2.6.1.3. By Drug Type
7.2.6.1.4. By Therapeutic Area
7.2.6.1.5. By End User
7.2.6.2. Mexico
7.2.6.2.1. By Type
7.2.6.2.2. By Process
7.2.6.2.3. By Drug Type
7.2.6.2.4. By Therapeutic Area
7.2.6.2.5. By End User
7.2.6.3. Argentina
7.2.6.3.1. By Type
7.2.6.3.2. By Process
7.2.6.3.3. By Drug Type
7.2.6.3.4. By Therapeutic Area
7.2.6.3.5. By End User
7.2.6.4. Peru
7.2.6.4.1. By Type
7.2.6.4.2. By Process
7.2.6.4.3. By Drug Type
7.2.6.4.4. By Therapeutic Area
7.2.6.4.5. By End User
7.2.6.5. Rest of Latin America
7.2.6.5.1. By Type
7.2.6.5.2. By Process
7.2.6.5.3. By Drug Type
7.2.6.5.4. By Therapeutic Area
7.2.6.5.5. By End User
8. Middle East & Africa Drug Discovery Services Market
8.1. Market Size & Forecast, 2019-2029
8.1.1. By Value (USD Billion)
8.2. Market Share & Forecast
8.2.1. By Type
8.2.2. By Process
8.2.3. By Drug Type
8.2.4. By Therapeutic Area
8.2.5. By End User
8.2.6. By Country
8.2.6.1. Saudi Arabia
8.2.6.1.1. By Type
8.2.6.1.2. By Process
8.2.6.1.3. By Drug Type
8.2.6.1.4. By Therapeutic Area
8.2.6.1.5. By End User
8.2.6.2. UAE
8.2.6.2.1. By Type
8.2.6.2.2. By Process
8.2.6.2.3. By Drug Type
8.2.6.2.4. By Therapeutic Area
8.2.6.2.5. By End User
8.2.6.3. Qatar
8.2.6.3.1. By Type
8.2.6.3.2. By Process
8.2.6.3.3. By Drug Type
8.2.6.3.4. By Therapeutic Area
8.2.6.3.5. By End User
8.2.6.4. Kuwait
8.2.6.4.1. By Type
8.2.6.4.2. By Process
8.2.6.4.3. By Drug Type
8.2.6.4.4. By Therapeutic Area
8.2.6.4.5. By End User
8.2.6.5. South Africa
8.2.6.5.1. By Type
8.2.6.5.2. By Process
8.2.6.5.3. By Drug Type
8.2.6.5.4. By Therapeutic Area
8.2.6.5.5. By End User
8.2.6.6. Nigeria
8.2.6.6.1. By Type
8.2.6.6.2. By Process
8.2.6.6.3. By Drug Type
8.2.6.6.4. By Therapeutic Area
8.2.6.6.5. By End User
8.2.6.7. Algeria
8.2.6.7.1. By Type
8.2.6.7.2. By Process
8.2.6.7.3. By Drug Type
8.2.6.7.4. By Therapeutic Area
8.2.6.7.5. By End User
8.2.6.8. Rest of MEA
8.2.6.8.1. By Type
8.2.6.8.2. By Process
8.2.6.8.3. By Drug Type
8.2.6.8.4. By Therapeutic Area
8.2.6.8.5. By End User
9. Competitive Landscape
9.1. List of Key Players and Their Offerings
9.2. Global Drug Discovery Services Company Market Share Analysis, 2022
9.3. Competitive Benchmarking, By Operating Parameters
9.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships)
10. Impact of Covid-19 on Global Drug Discovery Services Market
11. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)
11.1. General Electric
11.2. Eurofins Scientific
11.3. Syngene International Limited
11.4. Wuxi AppTec
11.5. Frontage Labs
11.6. Domainex
11.7. WIL Research Laboratories LLC
11.8. Shanghai Medicilon, Inc.
11.9. Labcorp Drug Development
11.10. Jubilant Biosys Ltd.
11.11. Evotec
11.12. Shanghai ChemPartner
11.13. Charles River Laboratories
11.14. Merck & Co. Inc.
11.15. Thermo Fisher Scientific Inc.
11.16. Other Prominent Players
12. Key Strategic Recommendations
13. Research Methodology
13.1. Qualitative Research
13.1.1. Primary & Secondary Research
13.2. Quantitative Research
13.3. Market Breakdown & Data Triangulation
13.3.1. Secondary Research
13.3.2. Primary Research
13.4. Breakdown of Primary Research Respondents, By Region
13.5. Assumptions & Limitations